Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

Endocrine-Related Cancer

Volumn 6, Issue 3, 1999, Pages 373-387

  Nicholson, R I ^a   McClelland, R A ^a   Robertson, J F R ^b   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; STEROID HORMONE;

BREAST CANCER; CANCER RESEARCH; ENDOCRINE SYSTEM; HORMONE ACTION; HUMAN; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; ESTROGENS; FEMALE; GROWTH SUBSTANCES; HUMANS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0032887942     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060373     Document Type: Review

References (160)

1. Agadir A, Shealy YF, Hill DL & Zhang X 1997 Retinyl methyl ether down-regulates activator protein 1 transcriptional activation in breast cancer cells. Cancer Research 57 3444-3450.
2. Alessi DR, Cuenda A, Cohen P, Dudley DT & Saltiel AR 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. Journal of Biological Chemistry 270 27489-27494.
3. Ali S, Metzger D, Bornert JM & Chambon P 1993 Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO Journal 12 1153-1160.
4. Amundadottir LT & Leder P 1998 Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16 737-746.
5. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blarney RW, Nicholson RI & Robertson JFR 1995 Expression of Ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer 72 1259-1266.
6. Arnold SF, Obourn JD, Jaffe H & Notides AC 1994 Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Molecular Endocrinology 8 1208-1214.
7. Arnold SF, Melamed M, Vorojeikina DP, Notides AC & Sasson S 1997 Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Molecular Endocrinology 11 48-53.
8. Aronica SM & Katzenellenbogen BS 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7 743-752.
9. Astruc ME, Chabret C, Bali P, Gagne D & Pons M 1995 Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136 824-832.
10. Badia E, Duchesne MJ, Astruc M, Fuentes M, Gagne D, Nicolas JC & Pons M 1995 Modulation of cellular response expression during prolonged treatment with antiestrogens. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 189 755-764.
11. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC & Norton L 1996 Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 14 737-744.
12. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME & Salomon DS 1988 Expression of transforming growth factor-alpha and its mRNA in human breast cancer: Its regulation by oestrogen and its possible functional significance. Molecular Endocrinology 2 543-555.
13. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A & Hassell JA 1997 HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15 1513-1525.
14. Berry M, Metzger D & Chambon P 1990 Role of two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. FMBO Journal 9 2811-2818.
15. Berthois Y, Dong XF & Martin PM 1989 Regulation of epidermal growth factor receptor by oestrogen and antioestrogen in the human breast cancer cell line MCF-7. Biochemical and Biophysical Research Communications 159 126-131.
16. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, Mackman N, Ziegler R & Nawroth PP 1997 The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thrombosis und Haemostasis 77 772-782.
17. Bland KI, Konstadoulakis MM, Vezeridis MP & Wanebo HJ 1995 Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Annals of Surgery 221 706-718.
18. Borg A, Baldetorp B, Ferno M, Olsson H & Sigurdsson H 1992 c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. International Journal of Cancer 51 687-691.
19. Brunner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME & Cullen KJ 1993 Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). European Journal of Cancer 29 562-569.
20. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
21. Callans LS, Naama H, Khandelwal M, Plotkin R & Jardines L 1995 Raf-1 protein expression in human breast cancer cells. Annals of Surgical Oncology 2 38-42.
22. Casalini P, Menard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM & Segal S 1997 Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. International Journal of Cancer 72 631-636.
23. Castano E, Vorojeikina DP & Notides AC 1997 Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochemical Journal 326 149-157.
24. Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW & Benz CC 1997 ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 14 1617-1622.
25. Chen HW & Huang HC 1998 Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. British Journal of Pharmacology 124 1029-1040.
26. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, Reczek P, Chambon P & Gronemeyer H 1995 RAR-specific agonist/antagonists which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation. EMBO Journal 14 1187-1197.
27. Cho H & Katzenellenbogen BS 1993 Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Molecular Endocrinology 7 441-452.
28. Chrysogelos SA, Yarden RI, Lauber AH & Murphy JM 1994 Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Research and Treatment 31 227-236.
29. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco & Salomon DS 1991 Expression of transforming growth factor alpha in breast cancer. Annals of Oncology 2 169-182.
30. Clark JW, Santos-Moore A, Stevenson LE & Frackelton AR Jr 1996 Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the Ras signaling pathway. International Journal of Cancer 65 186-191.
31. Clarke RB, Howell A, Potten CS & Anderson E 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 57 4987-4991.
32. Daly RJ, Binder MD & Sutherland RL 1994 Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9 2723-2727.
33. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G & De Bortoli M 1991 c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. International Journal of Cancer 47 833-838.
34. Dauvois S, Danielian PS, White R & Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences of the USA 89 4037-4041.
35. Davis RJ 1995 Transcriptional regulation by MAP kinases. Molecular Reproduction and Development 42 459-467.
36. Dean C, Modjtahedi H, Eccles S, Box G & Styles J 1994 Immunotherapy with antibodies to the EGF receptor. International Journal of Cancer 8 (Suppl) 103-107.
37. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blarney RW, Bundred NJ, Robertson JF, Saunders C & Baum M 1994 Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research 54 408-414.
38. Diamond MI, Miner JN, Yoshinaga SK & Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249 1266-1272.
39. Duan R, Porter W & Safe S 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139 1981-1990.
40. Dubik D & Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 1587-1594.
41. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA & Cross-Doersen DE 1996 Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth and Differentiation 7 351-359.
42. Eccles SA, Modjtahedi H, Box G, Court W, Sandle J & Dean CJ 1994 Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14 337-348.
43. Eisenberger MA, Sinibaldi V & Reyno L 1995 Suramin. Cancer Practice 3 187-189.
44. Ennis BW, Lippman ME & Dickson RB 1991 The EGF receptor system as a target for antitumor therapy. Cancer Investigation 9 553-562.
45. Fanjul AN, Bouterfa H, Dawson MI & Pfahl MA 1996 Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Research 56 1571-1577.
46. Fiddes RJ, Janes PW, Sanderson GM, Sivertsen SP, Sutherland RL & Daly RJ 1995 Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth and Differentiation 6 1567-1577.
47. Freiss G & Vignon F 1994 Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Molecular Endocrinology 8 1389-1396.
48. Freiss G, Prebois C, Rochefort H & Vignon F1990 Anti-steroidal and anti-growth factor activities of anti-oestrogens. Journal of Steroid Biochemistry and Molecular Biology 37 777-781.
49. Freiss G, Puech C & Vignon F 1998 Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Molecular Endocrinology 12 568-579.
50. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW & Bridges AJ 1994 A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265 1093-1095.
51. Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P & Collins DC 1998 Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemotherapy and Pharmacology 41 117-124.
52. Gangolli EA, Conneely OM & O'Malley BW 1997 Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line. Journal of Steroid Biochemistry and Molecular Biology 61 1-9.
53. Gee JMW, Ellis IO, Robertson JFR, Willsher P, McClelland RA, Hewitt KN, Blarney RW & Nicholson RI 1995 Immunocytochemical localization of FOS protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer 64 269-273.
54. Gee JWM, McClelland RA & Nicholson RI 1996 Growth factors and endocrine sensitivity in breast cancer. In Hormone Dependent Cancer, pp 169-197. Eds JR Pasqualini & BS Katzenellenbogen. Marcel Dekker Publishing.
55. Gee, JMW, Willsher P, Kenny FS, Robertson JFR, Pinder SE, Ellis IO & Nicholson RI 1999 Endocrine response and resistance in breast cancer: A role for the transcription factor FOS. International Journal of Cancer 84 54-61.
56. Geiger T, Muller M, Dean NM & Fabbro D 1998 Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anti Cancer Drug Design 13 35-45.
57. Gibson MK, Nemmers LA, Beckman WC Jr, Davis VL, Curtis SW & Korach KS 1991 The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129 2000-2010.
58. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH & Shaw PE 1995 ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and trans-activation. EMBO Journal 14 951-962.
59. Gordge PC, Hulme MJ, Clegg RA & Miller WR 1996 Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. European Journal of Cancer 32A 2120-2126.
60. Harris AL 1997 EGF Receptor as a target for therapy and interactions with angiogenesis. In EGF Receptor in Tumor Growth and Progression, pp 3-17. Eds RB Lichtner & RN Harkins. Ernst Schering Research Foundation Workshop 19. Berlin, Heidelberg: Springer-Verlag.
61. Heimbrook DC & Oliff A 1998 Therapeutic intervention and signaling. Current Opinion in Cell Biology 10 284-288.
62. Hiramatsu T, Imoto M, Koyano T & Umezawa K 1993 Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia. Cancer Letters 73 161-166.
63. Holt JT, Arteaga CB, Robertson D & Moses HL 1996 Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Human Gene Therapy 7 1367-1380.
64. Hori T, Kondo T, Tsuji T, Imoto M, Umezawa K, Ekimoto H & Hiratsuka M 1992 Inhibition of tyrosine kinase and src oncogene functions by stable erbstatin analogues. Journal of Antibiotics 45 280-282.
65. Howell A, DeFriend D, Robertson J, Blarney R & Walton P 1995 Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 29-30.
66. Howell A, DeFriend DJ, Robertson JF, Blarney RW, Anderson L, Anderson E, Sutcliffe FA & Walton P 1996 Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. British Journal of Cancer 74 300-308.
67. Howell A, Clarke RB & Anderson E 1997 Oestrogens, Beatson and endocrine therapy. Endocrine-Related Cancer 4 371-380.
68. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA & Dong Z 1997 Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proceedings of the National Academy of Sciences of the USA 94 5826-5830.
69. Huang TS, Kuo ML, Lin JK & Hsieh JS 1995 A labile hyperphosphorylated c-Fos protein is induced in mouse fibroblast cells treated with a combination of phorbol ester and anti-tumor promoter curcumin. Cancer Letters 96 1-7.
70. Jeschke M, Wels W, Dengler W, Imber R, Stocklin E & Groner B 1995 Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. International Journal of Cancer 60 730-739.
71. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18 1978-1984.
72. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H & Herrlich P 1990 Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid. Cell 62 1189-2104.
73. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE & Nicholson RI 1997 New EGF-R selective tyrosine kinase inhibitor reveals vriable growth responses in prostate carcinoma cell lines PC-3 and DU-145. International Journal of Cancer 71 1010-1018.
74. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E & Kawashima H 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
75. Kawada M, Fukazawa H, Mizuno S & Uehara Y 1997 Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras. Biochemical and Biophysical Research Communications 231 735-737.
76. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA & Sigman CC 1996 Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemo-preventives. Cancer Epidemiology Biomarkers and Prevention 5 657-666.
77. Kerppola TK, Luk D & Curran T 1993 Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Molecular and Cellular Biology 13 3782-3791.
78. Klijn JG, Berns PM, Schmitz PI & Foekens JA 1992 The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Reviews 13 3-17.
79. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R & Dickson RB 1987 Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 417-428.
80. Kobayashi D, Watanabe N, Yamauchi N, Tsuji N, Sato T, Sasaki H, Okamoto T & Niitsu Y 1997 Protein kinase C inhibitors augment tumor-necrosis-factor-induced apoptosis in normal human diploid cells. Chemotherapy 43 415-423.
81. Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD & Oliff A 1995 Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Journal of Cellular Biochemistry 22 (Suppl) 145-150.
82. Kolibaba KS & Druker BJ 1997 Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta 1333 F217-F248.
83. Kraus WL, McInerney EM & Katzenellenbogen BS 1995 Ligand-dependent, transcriptionally productive association of the amino-and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proceedings of the National Academy of Sciences of the USA 92 12314-12318.
84. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L & Parwaresch R 1993 Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Research 53 1956-1961.
85. Kuiper GGJM & Brinkmann AO 1994 Steroid hormone receptor phosphorylation: is there a physiological role? Molecular and Cellular Endocrinology 100 103-107.
86. Kumar V, Green S, Stack G, Berry M, Jin JR & Chambon P 1987 Functional domains of the human estrogen receptor. Cell 51 941-951.
87. Lahooti H, Thorsen T & Aakvaag A 1998 Modulation of mouse estrogen receptor transcription activity by protein kinase C delta. Journal of Molecular Endocrinology 20 245-259.
88. Larsen SS, Madsen MW, Jensen BL & Lykkesfeldt AE 1997 Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. International Journal of Cancer 72 1129-1136.
89. Lawrence DS & Niu J 1998 Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacology and Therapeutics 77 81-114.
90. Lee AV, Weng CN, Jackson JG & Yee D 1997 Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. Journal of Endocrinology 152 39-47.
91. Lee DK, Kim B, Lee SG, Gwon HJ, Moon EY, Hwang HS, Seong SK, Lee M, Lim MJ, Sung HJ, Shin DH, Yoon SJ & Yang CH 1998 Momordins inhibit AP-1 function and cell proliferation. Anticancer Research 18 119-124.
92. Le Goff P, Montano MM, Schodin DJ & Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. Journal of Biological Chemistry 269 4458-4466.
93. Lehrer S, O'Shaughnessy J, Song HK, Levine E, Savoretti P, Dalton J, Lipsztein R, Kalnicki S & Bloomer WD 1989 Activity of pp60c-src protein kinase in human breast cancer. Mount Sinai Journal of Medicine 56 83-85.
94. Levitzki A 1996 SRC as a target for anti-cancer drugs. Anti Cancer Drug Design 11 175-182.
95. Linardopoulos S, Malliri A, Pintzas A, Vassilaros S, Tsikkinis A & Spandidos DA 1990 Elevated expression of AP-1 activity in human breast tumors as compared with normal adjacent tissue. Anticancer Research 10 1711-1713.
96. Lukas J, Bartkova J & Bartek J 1996 Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Molecular and Cellular Biology 16 6917-6925.
97. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S & Sorvillo JM 1991 Expression of neu protein, EGFR, and transforming growth factor alpha in breast cancer: Correlation with clinicopathological parameters. American Journal of Pathology 138 1527-1534.
98. McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blarney RW, Wakeling AE & Nicholson RI 1996 Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Research and Treatment 41 31-41.
99. McDonnell DP, Dana SL, Hoener PA, Lieberman BA, Imhof MO & Stein RB 1995 Cellular mechanisms which distinguish between hormone-and antihormone-activated estrogen receptor. Annals of the New York Academy of Sciences 761 121-137.
100. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D & Dean NM 1997 Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti cancer therapeutics. Anti Cancer Drug Design 12 315-326.
101. Mangiarotti R, Danova M, Alberici R & Pellicciari C 1998 Alltrans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. British Journal of Cancer 77 186-191.
102. Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K & Yamamoto T 1993 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proceedings of the National Academy of Sciences of the USA 90 10803-10807.
103. Matsui Y, Halter SA, Holt JT, Hogan BL & Coffey RJ 1990 Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61 1147-1155.
104. Melner MH 1996 Physiological inhibitors of protein kinase C. Biochemical Pharmacology 51 869-877.
105. Migliaccio A, Pagano M & Auricchio F 1993 Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 8 2183-2191.
106. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R & Karin M 1994 c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Molecular and Cellular Biology 14 6683-6688.
107. Mohamood AS, Gyles P, Balan KV, Hollis VW, Eckberg WR, Asseffa A, Han Z, Wyche JH & Anderson WA 1997 Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines. Journal of Submicroscopic Cytology and Pathology 29 1-17.
108. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF & Freier SM 1992 Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. Journal of Biological Chemistry 267 19954-19962.
109. Monia BP, Johnston JF, Geiger T, Muller M & Fabbro D 1996 Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine 2 668-675.
110. Morishita S, Niwa K, Ichigo S, Hori M, Murase T, Fujimoto J & Tamaya T1995 Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Cancer Letters 97 225-231.
111. Musgrove EA, Hamilton JA, Lee CS, S weeney KJ, Watts CK & Sutherland RL 1993 Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology 13 3577-3587.
112. Nagpal S, Athanikar J & Chandraratna RA 1995 Separation of transactivation and API antagonism functions of retinoic acid receptor alpha. Journal of Biological Chemistry 270 923-927.
113. Newmark HL 1997 Squalene, olive oil, and cancer risk: a review and hypothesis. Cancer Epidemiology Biomarkers and Prevention 61101-1103.
114. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C & Chambon P 1990 Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO Journal 9 4443-4454.
115. Nicholson RI & Gee JWM 1996 Growth factors and modulation of endocrine response in breast cancer. In Hormones and Cancer, pp 227-261. Ed WV Vedeckis. Boston: Birkhauser.
116. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO & Blarney RW 1993 Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 29A 1018-1023.
117. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO & Blarney RW 1994a Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Research 54 1684-1689.
118. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO & Blarney RW 19942b Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Research and Treatment 29 117-125.
119. Nicholson RI, Gee JWM, Manning DL, Wakeling AE & Katzenellenbogen BS 1995a Responses to pure antioestrogens (ICI 164384 and ICI 182780) in oestrogen sensitive and resistant experimental and clinical breast cancer. Annals of the New York Academy of Sciences 761 148-163.
120. Nicholson RI, Gee JMW, Francis AB, Manning DL, Wakeling AE & Katzenellenbogen BS 1995b Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocrine-Related Cancer 2 115-121.
121. Nicholson RI, Gee JMW, Jones H, Harper ME, Wakeling AE, Willsher P & Robertson JFR 1997 erbB Signalling and endocrine sensitivity of human breast cancer. In EGF Receptor in Tumour Growth and Progression, pp 105-128. Eds RB Lichtner & RN Harkins. Boston: Springer-Verlag.
122. Nicholson S, Halcrow P, Fardon JR, Sainsbury JRC, Chambers P & Harris AL 1989 Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i 182-185.
123. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E & Vinson C 1997 A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. Journal of Biological Chemistry 272 18586-18594.
124. Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki K, Naganawa H, Takeuchi T, Tatsuta K & Umezawa K 1989 Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. Journal of Natural Products 52 1252-1257.
125. Osborne CK & Coronado-Heinsohn E 1996 Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin. Cancer Journal from Scientific American 2 175.
126. Pendurthi UR, Williams JT & Rao LV 1997 Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arteriosclerosis, Thrombosis and Vascular Biology 17 3406-3413.
127. Pfahl M 1993 Nuclear receptor/AP-1 interaction. Endocrine Reviews 14 651-658.
128. Philip PA & Harris AL 1995 Potential for protein kinase C inhibitors in cancer therapy. Cancer Treatment and Research 78 3-27.
129. Philips A, Chalbos D & Rochefort H 1993 Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. Journal of Biological Chemistry 268 14103-14108.
130. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets es trogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
131. Pratt WB & Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews 18 306-360.
132. Reuveni H, Gitler A, Poradosu E, Gilon C & Levitzki A 1997 Synthesis and biological activity of semipeptoid farnesyl-transferase inhibitors. Bioorganic and Medicinal Chemistry 5 85-92.
133. Rochefort H 1995 Oestrogen-and anti-oestrogen-regulated genes in human breast cancer. Ciba Foundation Symposium 191 254-265.
134. Salomon DS, Kim N, Saeki T & Ciardiello F 1990 Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells 2 389-397.
135. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL & Lee DC 1990 Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61 1121-1135.
136. Scherr M, Grez M, Ganser A & Engels JW 1997 Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. Journal of Biological Chemistry 272 14304-14313.
137. Segnitz B & Gehring U 1995 Subunit structure of the nonactivated human estrogen receptor. Proceedings of the National Academy of Sciences of the USA 92 2179-2183.
138. Shiu RP, Watson PH & Dubik D 1993 c-myc oncogene expression in estrogen-dependent and -independent breast cancer. Clinical Chemistry 39 353-355.
139. Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM & Hellstrom I 1995 HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. Journal of Biological Chemistry 270 7625-7630.
140. Singh SV, Mohan RR, Agarwal R, Benson PJ, Hu X, Rudy MA, Xia H, Katoh A, Srivastava SK, Mukhtar H, Gupta V & Zaren HA 1996 Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth m vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochemical and Biophysical Research Communications 225 660-665.
141. Sivaraman VS, Wang H, Nuovo GJ & Malbon CC 1997 Hyperexpression of mitogen-activated protein kinase in human breast cancer. Journal of Clinical Investigation 99 1478-1483.
142. Smith CL, Conneely OM & O'Malley BW 1993 Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proceedings of the National Academy of Sciences of the USA 90 6120-6124.
143. Tang P, Hung MC & Klostergaard J 1994 TNF cytotoxicity: effects of HER-2/neu expression and inhibitors of ADP-ribosylation. Lymphokine and Cytokine Research 13 117-123.
144. Tiniakos DG, Scott LE, Corbett IP, Piggott NH & Home CH 1994 Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. Journal of Pathology 172 19-26.
145. Toi M, Mukaida H, Wada T, Hirabayashi N, Toge T, Hori T & Umezawa K 1990 Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. European Journal of Cancer 26 722-724.
146. Trowbridge JM, Rogatsky I & Garabedian MJ 1997 Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proceedings of the National Academy of Sciences of the USA 94 10132-10137.
147. Tzeng DZ & Klinge CM 1996 Phosphorylation of purified estradiol-liganded estrogen receptor by casein kinase II increases estrogen response element binding but does not alter ligand stability. Biochemical and Biophysical Research Communications 223 554-560.
148. Umekita Y, Enokizono N, Sagara Y, Kuriwaki K, Takasaki T, Yoshida A & Yoshida H 1992 Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. Virchows Archiv A - Pathological Anatomy and Histopathology 420 345-351.
149. Umezawa K 1995 Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Advances in Enzyme Regulation 35 43-53.
150. Umezawa K, Ohse T, Yamamoto T, Koyano T & Takahashi Y 1994 Isolation of a new vinca alkaloid from the leaves of Ervatamia microphylla as an inhibitor of ras functions. Anticancer Research 14 2413-2417.
151. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA & Woodburn JR 1996 Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Research and Treatment 38 67-73.
152. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA & Woodburn JR 1997 New targets for therapeutic attack. Endocrine-Related Cancer 4 351-355.
153. Walker KJ, Price-Thomas JM, Candlish W & Nicholson RI 1991 Influence of the antioestrogen tamoxifen on normal breast tissue. British Journal of Cancer 64 764-768.
154. Walker KJ, McClelland RA, Candlish W, Blarney RW & Nicholson RI 1992 Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. European Journal of Cancer 28 34-37.
155. Wang C, Thor AD, Moore DH II, Zhao Y, Kerschmann R, Stern R, Watson PH & Turley EA 1998 The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clinical Cancer Research 4 567-576.
156. Ward WHJ, Cook, PN, Slater AM, Davies DH, Holdgate GA & Green LR 1994 Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochemical Pharmacology 48 659-666.
157. Webb P, Lopez GN, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-Iike effects of antiestrogens. Molecular Endocrinology 9 443-456.
158. Wiechen K & Dietel M 1995 c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. International Journal of Cancer 63 604-608.
159. White R & Parker MG 1998 Molecular mechanisms of steroid hormone action. Endocrine-Related Cancer 5 1-14.
160. Xu YX, Pindolia KR, Janakiraman N, Chapman RA & Gautam SC 1997 Curcumin inhibits ILl alpha and NF-alpha induction of AP-1 and NF-κB DNA-binding activity in bone marrow stromal cells. Hematopathology and Molecular Hematology 11 49-62.